-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Metagenomi Therapeutics, Lowers Price Target to $9

Benzinga·05/12/2026 13:27:26
Listen to the news
Wells Fargo analyst Yanan Zhu maintains Metagenomi Therapeutics (NASDAQ:MGX) with a Overweight and lowers the price target from $12 to $9.